Form 4: IOVANCE COO Bilinsky Reports RSU Vesting, Tax Withholding

IOVANCE BIOTHERAPEUTICS' Chief Operating Officer, Igor Bilinsky, reported the vesting of 31,246 restricted stock units and the subsequent withholding of 16,628 shares for tax obligations.

Summary

• Igor Bilinsky, Chief Operating Officer of IOVANCE BIOTHERAPEUTICS, INC. (IOVA), reported transactions related to his beneficial ownership.
• On March 5, 2026, 31,246 restricted stock units (RSUs) vested, converting into common stock.
• Concurrently, 16,628 shares of common stock were withheld by the Issuer to satisfy mandatory tax withholding requirements upon the RSU vesting, at a price of $4.58 per share.
• Following these transactions, Bilinsky beneficially owns 125,766 shares of common stock directly.
• He also holds 62,504 remaining restricted stock units, which are scheduled to vest in equal quarterly installments.

Sentiment

Score: 5

Explanation: StockSavvy.ai views this as a neutral event, representing a routine executive compensation transaction with no direct operational or financial impact on the company's performance.

Positives

• Vesting of RSUs indicates the executive is receiving compensation as planned, aligning interests with shareholders through equity ownership.

Future Outlook

Remaining Restricted Stock Units (RSUs) held by Igor Bilinsky will vest in equal quarterly installments, indicating a continued long-term incentive structure for the executive.

Management Comments

• The transactions represent the routine vesting of previously granted restricted stock units and the subsequent withholding of shares to cover tax obligations.

Industry Context

StockSavvy.ai notes that routine Form 4 filings, such as this one detailing RSU vesting and tax withholding, are common for executives in the biotechnology sector. These transactions reflect standard compensation practices designed to align executive interests with long-term shareholder value, particularly in companies like IOVANCE BIOTHERAPEUTICS which are often in development phases.

Comparison to Industry Standards

• Executive compensation through Restricted Stock Units (RSUs) with vesting schedules is a standard practice across the biotechnology and pharmaceutical industries, similar to companies like Amgen, Gilead Sciences, or Moderna.
• The withholding of shares for tax purposes upon RSU vesting is also a common mechanism, ensuring compliance with tax laws without requiring the executive to sell shares on the open market immediately, a practice seen in many publicly traded companies across various sectors.

Stakeholder Impact

• Shareholders: Minimal direct impact as this is a routine compensation event. It reflects the ongoing alignment of executive incentives with company performance through equity ownership.

Next Steps

• The remaining 62,504 Restricted Stock Units held by Igor Bilinsky are scheduled to vest in equal quarterly installments.

Key Dates

Recommendation

This Form 4 filing details a routine executive compensation event (RSU vesting and tax withholding) and does not provide new information regarding the company's operational performance, financial health, or strategic direction that would warrant a change in investment recommendation. The transaction is expected and reflects standard practice.

Keywords

IOVANCE BIOTHERAPEUTICS, IOVA, Form 4, Insider Transaction, RSU Vesting, Stock Compensation, Igor Bilinsky, Chief Operating Officer